Covered recipient · General Payments record
BAEKCHEOL LEE
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2023
$1,317.11
- Reported across 68 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $457.16 | 17 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Vertos Medical, Inc. | $136.55 | 2 |
| Novo Nordisk AS | $64.72 | 3 |
| ABBVIE INC. | $54.66 | 3 |
| Daiichi Sankyo Inc. | $46.29 | 2 |
| Lilly USA, LLC | $42.31 | 2 |
| GlaxoSmithKline, LLC. | $35.76 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $32.68 | 1 |
| Amgen Inc. | $26.03 | 1 |
| IBSA Pharma Inc. | $18.16 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.22 | 01/04/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1006011849 | CMS |
| ABBVIE INC. | $17.55 | 06/03/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1006011851 | CMS |
| ABBVIE INC. | $22.89 | 08/08/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1006011853 | CMS |
| Amgen Inc. | $26.03 | 05/05/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1020248187 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $32.68 | 04/14/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997100137 | CMS |
| Daiichi Sankyo Inc. | $26.50 | 01/31/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1006393299 | CMS |
| Daiichi Sankyo Inc. | $19.79 | 05/09/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1006410361 | CMS |
| GlaxoSmithKline, LLC. | $18.08 | 02/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1004231871 | CMS |
| GlaxoSmithKline, LLC. | $17.68 | 06/20/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1004236217 | CMS |
| IBSA Pharma Inc. | $18.16 | 02/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 999729357 | CMS |
| Lilly USA, LLC | $16.25 | 05/19/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1032719125 | CMS |
| Lilly USA, LLC | $26.06 | 07/06/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1032455912 | CMS |
| Novo Nordisk Inc | $22.07 | 03/21/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1001576871 | CMS |
| Novo Nordisk Inc | $21.11 | 04/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1001576843 | CMS |
| Novo Nordisk Inc | $21.54 | 06/16/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1001576857 | CMS |
| Vertos Medical, Inc. | $94.06 | 06/14/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1050719461 | CMS |
| Vertos Medical, Inc. | $42.49 | 09/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1050716879 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023
- Source files
- Dataset page · Bulk file · PY2021 , PY2022 , PY2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.